Imaging tumor lactate is feasible for identifying intermediate-risk prostate cancer patients with postsurgical biochemical recurrence (Proceedings of the National Academy of Sciences, 2023)

(untitled) - Sushentsev, N; Hamm, G; Richings, J; McLean, MA; Menih, IH; Ayyappan, V; Mills, IG; Warren, AY; Gnanapragasam, VJ; Barry, ST; Goodwin, RJA; Gallagher, FA; et al.